Breast Lump Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Breast lump surgery encompasses a range of surgical procedures aimed at removing discrete masses from the breast tissue for diagnostic evaluation, symptom relief, or curative treatment of malignancy. The specific procedure depends on the nature of the lump (benign or malignant), its size and location, the patient's preferences, and the clinical goals — which may be diagnostic (excisional biopsy), therapeutic (fibroadenoma excision), or oncologically curative (wide local excision for breast cancer).

Excisional biopsy removes the entire lesion along with a small cuff of surrounding tissue for pathological examination. It is performed under local or general anaesthesia depending on lesion size and depth, typically through a curved incision following Langer's lines of skin tension for optimal cosmetic outcome. Lesions not palpable at the time of surgery — detected on imaging only — are localised preoperatively using wire-guided localisation, radioactive seed localisation, or SAVI Scout radar reflector systems, allowing the surgeon to identify and remove the precise area indicated on imaging.

For confirmed breast cancers, the surgical procedure is a wide local excision (WLE) or lumpectomy, which removes the tumour with a clear margin of surrounding healthy tissue (typically 2 mm or more). This is combined with sentinel lymph node biopsy for axillary staging. WLE is a breast-conserving surgery that preserves the breast and is combined with post-operative radiotherapy. The oncological outcomes of WLE plus radiotherapy are equivalent to mastectomy for appropriately selected tumour sizes and patient anatomy.

Breast lump surgery treats a spectrum of benign and malignant conditions. Fibroadenomas — the most common benign breast lump in young women, composed of glandular and fibrous tissue — are excised when they are large (greater than 3 cm), growing rapidly, causing discomfort, or when the patient prefers definitive removal over surveillance. Phyllodes tumours, which can range from benign to malignant, require wider excision margins than simple fibroadenomas to prevent recurrence. Cysts that are persistently symptomatic or showing complex features on ultrasound may be excised after aspiration attempts.

Malignant conditions treated by breast lump surgery include invasive ductal carcinoma, invasive lobular carcinoma, and ductal carcinoma in situ (DCIS) — all amenable to wide local excision when tumour size relative to breast volume is appropriate. Intraductal papillomas causing nipple discharge are surgically excised via microdochectomy (removal of the affected duct). Lipomas, sebaceous cysts, and fat necrosis lumps can also be surgically removed if symptomatic, growing, or causing patient concern after conservative management.

Candidates for breast lump surgery include patients with confirmed or highly suspicious malignant lumps requiring wide local excision, patients with benign lumps causing significant anxiety or discomfort, and patients with lesions that cannot be definitively diagnosed by needle biopsy alone (radiological-pathological discordance). Patients with large fibroadenomas greater than 3 cm, or smaller lesions that are symptomatic, are reasonable surgical candidates after thorough counselling regarding the alternative of surveillance.

Contraindications to breast-conserving surgery for cancer include tumours too large relative to the breast volume to achieve adequate excision while maintaining a cosmetically acceptable result, multifocal malignancy in separate quadrants, previous radiation to the same breast precluding post-operative radiotherapy, and patient preference for mastectomy. Patients with inflammatory breast cancer should not undergo primary surgical excision without preceding neoadjuvant chemotherapy. Medical contraindications to general anaesthesia may require the procedure to be performed under local anaesthesia with sedation.

Excisional biopsy removes the entire lesion under local or general anaesthesia, typically as a day case. For non-palpable lesions, image-guided wire localisation or newer wireless localisation systems (radioactive seed, SAVI Scout, Magseed) are placed on the morning of surgery to direct the surgeon to the correct area. The surgeon then excises the lesion with the localisation device, and intraoperative specimen radiography confirms adequate removal before wound closure.

Wide local excision for breast cancer involves removing the tumour plus a margin of histologically normal surrounding tissue. Intraoperative techniques including specimen ultrasonography, intraoperative ultrasound, and MarginProbe — a device that detects tumour at the specimen margin using radiofrequency spectroscopy — aim to reduce the rate of positive margins requiring re-excision. Oncoplastic breast surgery combines oncological excision with plastic surgery tissue rearrangement techniques (glandular flaps, local transposition flaps) to fill defects and maintain breast shape after larger excisions. Vacuum-assisted excision (VAE) allows complete removal of small fibroadenomas (up to 3 cm) through a single 3 mm nick in the skin under ultrasound guidance, avoiding open surgery entirely. Oncoplastic breast conservation combines lumpectomy with plastic surgical reshaping techniques (volume displacement or volume replacement) to achieve clear margins while maintaining breast shape and symmetry, avoiding mastectomy in women with up to 30–40% of breast volume requiring removal. Radioactive seed localisation (RSL) or RFID-tagged wire-free localisation allows scheduling flexibility over traditional wire-guided procedures.

For malignant lumps, wide local excision with clear margins combined with post-operative radiotherapy achieves equivalent long-term cancer-specific survival to mastectomy in appropriately selected patients, as demonstrated in the landmark Milan and NSABP B-06 randomised trials with over 20 years of follow-up. Breast conservation preserves body image and avoids the physical and psychological impact of mastectomy. Lymphoedema risk is significantly lower with sentinel lymph node biopsy alone (3 to 5%) compared with full axillary node dissection (20 to 25%).

For benign lumps, surgical excision provides definitive histological diagnosis, immediate relief from palpable or symptomatic lumps, resolution of patient anxiety, and eliminates the need for repeated surveillance imaging. Oncoplastic techniques achieve superior cosmetic outcomes after larger excisions compared with simple excision, reducing the incidence of breast deformity from 30% to less than 10% in studies at specialist oncoplastic centres.

Common complications include haematoma (2 to 5%), seroma (5 to 15% after larger excisions), wound infection (2 to 3%), and bruising. Changes in breast contour — including dimpling, asymmetry, and indentation at the excision site — occur in 10 to 30% of simple excision procedures and are reduced with oncoplastic techniques. Temporary or permanent sensory changes in the operated breast or nipple area affect a minority of patients.

For cancer surgery, the most clinically significant complication is a positive surgical margin — cancer cells found at the edge of the excised tissue — which requires re-excision to achieve clear margins and occurs in approximately 20 to 25% of initial excisions, though intraoperative margin assessment techniques reduce this rate. After sentinel lymph node biopsy, temporary seroma in the axilla (20 to 30%) and temporary shoulder stiffness are common and resolve within weeks. Lymphoedema occurs in approximately 3 to 5% of patients after SLNB alone. Wound complications at the breast excision site, including fat necrosis and skin necrosis at flap tips after oncoplastic procedures, occur in approximately 2 to 5% of cases.

Recovery from breast lump excision is generally swift. Most patients are discharged the same day or the following morning. Wound dressings are changed at one week, and sutures are removed or dissolve over two to three weeks. Normal daily activities including light work can be resumed within five to seven days. Driving and upper body exercise are restricted for one to two weeks. Axillary seroma following lymph node biopsy may require aspiration at the outpatient clinic one to three times in the weeks following surgery.

Histological results are typically available within five to seven days and are reviewed at an MDT meeting. If margins are clear for malignancy, post-operative planning (radiation, systemic therapy) proceeds. If margins are involved, re-excision is scheduled. Long-term follow-up for breast cancer patients includes clinical examination every six months for two years, then annually, plus annual mammography. Patients with benign excisions that proved histologically benign are usually discharged from follow-up after one confirmatory visit.

Breast lump excision in the United States costs $5,000 to $12,000 including facility fees, anaesthesia, and pathology, depending on whether the procedure is under local or general anaesthesia, whether lymph node biopsy is included, and the complexity of the lesion localisation required. Health insurance typically covers excision of suspicious or malignant lumps, while excision of confirmed benign lesions may be classified as elective.

At JCI-accredited centres in India, breast lump surgery including histopathology costs $500 to $2,000 depending on complexity. In Thailand and Turkey, the equivalent procedure costs $800 to $3,000. International patients travelling for breast cancer surgery typically combine lump excision with a complete treatment package. For patients with benign lumps seeking definitive removal at lower cost, medical tourism offers substantial savings of 50 to 70% compared with US or UK private rates, with comparable surgical quality at accredited centres.

For benign lumps including fibroadenomas confirmed by core needle biopsy, active surveillance with six-monthly ultrasound is a well-validated alternative to surgery. Most fibroadenomas in young women remain stable or regress over time, and surgical excision can be deferred indefinitely if the lesion remains stable and the patient is comfortable with monitoring. Vacuum-assisted excision (VAE) removes fibroadenomas up to 3 cm through a tiny skin nick under local anaesthesia with ultrasound guidance, avoiding open surgery with general anaesthesia entirely.

For malignant lumps, the alternative to wide local excision is mastectomy (total breast removal). This avoids the need for post-operative radiotherapy and is preferred in specific clinical scenarios (large tumour, multifocal disease, BRCA carrier, patient preference). Neither option is universally superior — the choice is individualised based on tumour biology, breast anatomy, patient preference, and access to radiotherapy. There is no non-surgical curative alternative to excision for breast cancer.